Phase II study of combined modality postremission therapy as determined by molecular response (adaptive regulation) in the treatment of acute promyelocytic leukemia (APL)
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Arsenic trioxide; Idarubicin; Lintuzumab; Tretinoin
- Indications Acute promyelocytic leukaemia
- Focus Therapeutic Use
- 16 Jan 2013 Biomarkers information updated
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 May 2007 Status change